AXIN2 and neoplasm: Figure 12A shows that the expression of AXIN2 was higher in the WNT subtypes than in all the other subtypes (F = 577.14, p < 1.0 × 10−300). Its expression was also higher than non-tumor samples in the Swartling dataset (p = 8.62 × 10−127). For AXIN2, high expression was associated with better survival (Figure 12B). Its hazard ratio was 0.64 (0.50–0.83, p = 6.09 × 10−5); elevated expression was associated with survival protection (Figure 12B). All individuals (N = 49) in the WNTα subtype had an elevated AXIN2 expression, while 15/21 in the WNTβ had an elevated AXIN2 expression.